Navigation Links
Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Date:4/18/2008

Trial Marks Third Study in Company's STEALTH C Clinical Program to Evaluate

Nitazoxanide in the Treatment of Chronic Hepatitis C

TAMPA, Fla., April 18 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that it has begun enrolling patients in a U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C. Preliminary data from the study is expected in the second half of 2008.

The study, STEALTH C-3 (Studies to Evaluate Alinia for Treatment of Hepatitis C), is a Phase II randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alpha-2a (Pegasys(R), Roche) and ribavirin (Copegus(R), Roche) in treatment naive patients with chronic hepatitis C infected with genotype 1.

The primary objective of STEALTH C-3 is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo. The trial will enroll 60 patients at 15 centers in the U.S.

"Earlier clinical studies in patients with chronic hepatitis C infected with genotype 4 have shown that nitazoxanide improves virologic response rates when used in combination with standard of care," said Dr. Emmet B. Keeffe, Chief Medical Officer of Romark. "This study and our ongoing STEALTH C-2 trial, are designed to evaluate the effect of treatment with nitazoxanide plus standard of care in patients with genotype 1. Future clinical trials will explore new combinations and treatment durations, including current and emerging HCV therapies."

STEALTH C Clinical Development Program

STEALTH C-3 is the latest in a series of clinical trials aimed at gaining a broad understanding of how nitazoxanide may benefit patients with chronic
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark Laboratories Raises $18 Million in Institutional Financing
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
9. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
10. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
11. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... FORT WORTH, Texas , December 18, 2014 ... is a networked software application/module that is used ... and related images. RIS comprises a patient tracking ... tracking system. The integration of RIS with HIS ... is used for patient registration and patient scheduling, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... reduce the use of mechanical ventilation with premature infants in ... affect those children,s outcomes while reducing the cost of care, ... The team, led by Bernadette Levesque, MD, ... and the Neonatal Intensive Care Unit (NICU) at St. Elizabeth,s ...
... SPRING, Md., June 10, 2011 The U.S. Food ... Merck,s redesigned drug container labels that include a new ... on product and strength differentiation. (Logo: ... the revision of 34 container labels for 16 solid ...
Cached Medicine Technology:Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3FDA Approves Redesigned Labels for Some Merck Drugs 2
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... ... best hospitals in the United States by U.S. News & World Report. , ... New York, NY (Vocus) July 16, 2009 -- The Mount Sinai Medical ... States by U.S. News & World Report. , , ,In the 2009-10 America,s Best Hospital issue, Mount ...
... , BOCA RATON, Fla., July 16 JAG ... further update of the status of its acquisition of CardioGenics ... closing date for the acquisition, currently scheduled for a date ... a date on or before July 24, 2009 to allow ...
... ... their practices and prepare for the future just launched on Monday. , ... (Vocus) July 16, 2009 -- The ... 25 years of combined experience in dental practice sales and appraisals, is the first membership-based, ...
... , , WASHINGTON, July 16 ... committees crafting the House version of a health care reform bill ... those revenues to a special fund to finance prevention and wellness ... taxes are an important tool in reducing the public health toll ...
... to higher risk of heart attack, stroke, agency says, ... Food and Drug Administration has begun a safety review ... an increased risk of heart attack, abnormal heart rhythm, ... Early results from the Evaluating the Clinical Effectiveness and ...
... , , , BEDFORD, Ohio, ... Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. ... by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO ...
Cached Medicine News:Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 2Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 3Health News:JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc. 2Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2Health News:Raise Federal Alcohol Tax to Finance Prevention Trust Fund, Partnership Urges House Chairmen 2Health News:FDA Investigating Safety of Asthma Drug Xolair 2Health News:Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: